Coherus Oncology Inc. (CHRS)
Company Description
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27.
It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors.
In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited.
The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025.
The company was incorporated in 2010 and is based in Redwood City, California.

Country | United States |
IPO Date | Nov 6, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 228 |
CEO | Dennis M. Lanfear |
Contact Details
Address: 333 Twin Dolphin Drive Redwood City, California United States | |
Website | https://www.coherus.com |
Stock Details
Ticker Symbol | CHRS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001512762 |
CUSIP Number | 19249H103 |
ISIN Number | US19249H1032 |
Employer ID | 27-3615821 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dennis M. Lanfear | Chairman, President & Chief Executive Officer |
Bryan J. McMichael | Chief Financial Officer |
Andy Rittenberg | Executive Vice President of General Counsel |
Dr. Rosh Dias M.D., MRCP | Chief Medical Officer |
Dr. Theresa M. Lavallee Ph.D. | Chief Development Officer & Chairman of Scientific Advisory Board |
Jodi Sievers | Vice President of Investor Relations & Corporate Communications |
Michael Chen | Senior Vice President of Commercial Analytics & Trade |
Rebecca Sunshine | Chief Human Resources Officer |
Richard L. Hameister | Chief Technical Officer |
Scott Saywell | Executive Vice President of Corporate Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Sep 08, 2025 | 8-K | Current Report |
Aug 07, 2025 | 10-Q | Quarterly Report |
Aug 07, 2025 | 8-K | Current Report |
Jul 03, 2025 | 8-K | Current Report |
Jun 13, 2025 | 4 | Filing |
Jun 13, 2025 | 4 | Filing |
Jun 13, 2025 | 4 | Filing |
Jun 13, 2025 | 4 | Filing |
Jun 13, 2025 | 4 | Filing |
Jun 13, 2025 | 4 | Filing |